参考文献/References:
[1] Antonopoulos AS,Antoniades C. The role of epicardial adipose tissue in cardiac biology:classic concepts and emerging roles[J]. J Physiol,2017,595(12):3907-3917.
[2] Iacobellis G. Epicardial adipose tissue in endocrine and metabolic diseases[J]. Endocrine,2014,46(1):8-15.
[3] Mazurek T,Zhang L,Zalewski A,et al. Human epicardial adipose tissue is a source of inflammatory mediators[J]. Circulation,2003,108(20):2460-2466.
[4] Cherian S,Lopaschuk GD,Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease[J]. Am J Physiol Endocrinol Metab,2012,303(8):E937-E949.
[5] Greulich S,de Wiza DH,Preilowski S,et al. Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function[J]. Cell Mol Med,2011,15(11):2399-2410.
[6] Greulich S,Maxhera B,Vandenplas G,et al. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction[J]. Circulation,2012,126(19):2324-2334.
[7]Hwang IC,Park HE,Choi SY. Epicardial adipose tissue contributes to the development of non-calcified coronary plaque: a 5-year computed tomography follow-up study[J]. Atheroscler Thromb,2017,24(3):262-274.
[8] Djaberi R,Schuijf JD,van Werkhoven JM,et al. Relation of epicardial adipose tissue to coronary atherosclerosis[J]. Atheroscler Thromb,2017,24(3):262-274.
[9] Ueno K,Anzai T,Jinzaki M,et al. Increased epicardial fat volume quantified by 64-multidetector computed tomography is associated with coronary atherosclerosis and totally occlusive lesions[J]. Circ J,2009,73(10):1927-1933.
[10]Taguchi R,Takasu J,Itani Y,et al. Pericardial fat accumulation in men as a risk factor for coronary artery disease[J]. Atherosclerosis,2001,157(1):203-209.
[11]Cetin M,Cakici M,Polat M,et al. Relation of epicardial fat thickness with carotid intima-media thickness in patients with type 2 diabetes mellitus[J].Int J Endocrinol,2013,2013:769175.
[12]Alberti KG,Zimmet PZ. Definition,diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J].Diabet Med,1998,15(7):539-553.
[13]王志富,朱苗霞,王志平. 2型糖尿病患者血糖波动与血管并发症关系的研究进展[J]. 心血管病学进展,2018,39(6):1064-1068.
[14]Zheng Y,Ley SH,Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol,2018,14(2):88-98.
[15]Iacobellis G,Ribaudo MC,Assael F,et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome:a new indicator of cardiovascular risk[J]. Clin Endocrinol Metab,2003,88(11):5163-5168.
[16]Iacobellis G,Barbaro G,Gerstein HC. Relationship of epicardial fat thickness and fasting glucose[J]. Int J Cardiol,2008,128(3):424-426.
[17]Malone JI,Hansen BC.Does obesity cause type 2 diabetes mellitus(T2DM)? Or is it the opposite?[J]. Pediatr Diabetes,2019,20(1):5-9.
[18]Reinhardt M,Cushman TR,Thearle MS,et al. Epicardial adipose tissue is a predictor of decreased kidney function and coronary artery calcification in youth- and early adult onset type 2 diabetes mellitus[J]. Endocrinol Invest,2019,42(8):979-986.
[19]Groves EM,Erande AS,Le C,et al. Comparison of epicardial adipose tissue volume and coronary artery disease severity in asymptomatic adults with versus without diabetes mellitus[J]. Am J Cardiol,2014,114(5):686-691.
[20]Wang CP,Hsu HL,Hung WC,et al. Increased epicardial adipose tissue(EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis[J]. Clin Endocrinol(Oxf),2009,70(6):876-882.
[21]Vasques AC,Pareja JC,Souza JR,et al. Epicardial and pericardial fat in type 2 diabetes:favourable effects of biliopancreatic diversion[J]. Obes Surg,2015,25(3):477-485.
[22]Sacks HS,Fain JN,Cheema P,et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes:changes associated with pioglitazone[J]. Diabetes Care,2011,34(3):730-733.
[23]Lima-Martínez MM,Paoli M,Rodney M,et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity:a pilot study[J].Endocrine,2016,51(3):448-455.
[24]Seker T,Turkoglu C,Harbalioglu H,et al. The impact of diabetes on the association between epicardial fat thickness and extent and complexity of coronary artery disease in patients with non-ST elevation myocardial infarction[J]. Kardiol Pol,2017,75(11):1177-1184.
[25]Marchington JM,Pond CM. Site-specific properties of pericardial and epicardial adipose tissue:the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro[J]. Int J Obes,1990,14(12):1013-1022.
相似文献/References:
[1]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[2]李嘉仪 黄龙祥 罗素新.钠-葡萄糖协同转运蛋白-2抑制剂在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
LI JiayiHUANG LongxiangLUO Suxin.SGLT-2 Inhibitors in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):1245.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.015]
[3]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[4]耿肖囡 肖东斌 魏鑫 惠学志.达格列净对心血管疾病的预防保护机制[J].心血管病学进展,2019,(8):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
GENG Xiaonan,XIAO Dongbin,WEI xin,et al.Preventive and Protective Mechanism of Dagliflozin for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1169.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.025]
[5]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(9):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[6]辛玉晶,刘昊凌.钠-葡萄糖协同转运蛋白２抑制剂与2型糖尿病心血管危险因素的研究进展[J].心血管病学进展,2020,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
XIN Yujing,LIU Haoling.SGLT-2 Inhibitors and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(9):235.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.005]
[7]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[8]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[9]张阳扬 尹德录.新型降糖药物在心力衰竭中的应用前[J].心血管病学进展,2020,(6):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
ZHANG Yangyang,YIN Delu.Prospect of New Glucose-lowering Drugs in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):599.[doi:10.16806/j.cnki.issn.1004-3934.20.06.010]
[10]吴易航 张宇辉 张健.SGLT2 i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展,2020,(8):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]
WU Yihang,ZHANG Yuhui,ZHANG Jian.Progresses on the Cardiovascular Protection of SGLT2 Inhibitor Empagliflozin in Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(9):787.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.001]